TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis

October 13, 2022

https://www.globenewswire.com/news-release/2022/10/13/2533739/8790/en/TG-Therapeutics-Announces-Data-Presentations-from-the-ULTIMATE-I-II-Phase-3-Trials-of-Ublituximab-in-Multiple-Sclerosis-to-be-Presented-at-the-2022-European-Committee-for-Treatment.html

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the schedule of data presentations, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2022 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 26 – 28, 2022, in Amsterdam, the Netherlands. Abstracts are now available online and can be accessed on the ECTRIMS meeting website at https://journals.sagepub.com/doi/epub/10.1177/13524585221123687. Details of the presentations are outlined below.

PRESENTATIONS:
Poster Presentation Title: Disability Changes in the Absence of Relapse in the Phase 3 ULTIMATE I and II Studies of ublituximab Versus teriflunomide in Participants With Relapsing Multiple Sclerosis

Read more at globenewswire.com

Related news for (TGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.